Malignant Mesothelioma clinical trials

Explore recruiting malignant mesothelioma clinical trials.

Recruiting malignant mesothelioma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Malignant Mesothelioma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)

Denmark, Sweden, Spain, Norway

Phase II and Phase III (Integrated) EU CTIS Study details

Malignant Mesothelioma trials by city

Malignant Mesothelioma clinical trials

Recruiting malignant mesothelioma studies right now

Olaparib in Patients With HRD Malignant Mesothelioma

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

Evaluation of Skin Tests in Biotherapy Allergies

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma

A Study of NX-1607 in Adults With Advanced Malignancies

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Also recruiting in Europe

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)

Malignant Mesothelioma trials by city

Other conditions